Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy

Source: PubMed. Author: Jean-Michel Scherrmann

Scherrmann JM. Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy [published online ahead of print, 2020 Aug 17]. Clin Pharmacol Ther. 2020;10.1002/cpt.2020. doi:10.1002/cpt.2020

Abstract

The antiviral use of azithromycin in COVID-19 was recently reported by Damle et al. Its combination with hydroxychloroquine did not aim at preventing bacterial super-infection as often believed, but at benefiting from their common lysosomotropic properties which buffer the acidic conditions (pH 4-5) of the endolysosomal lumen where SARS-CoV-2 transits following its ACE-2 receptor-mediated endocytosis. These two powerful cationic and amphiphilic drugs increase up to neutrality the intravesicular pH causing disorders in lysosomal functions such as enzyme inhibitions involved in the virus replication cycle. We recently hypothesized that the ATP-binding cassette ABCB1 (P-glycoprotein) could be involved in this reported synergistic effect.

Related: The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients

Harvey Risch, Yale School of Medicine “The Key to Defeating COVID-19 Already Exists. We Need to Start Using It

The Epoch Times – Adam Carolla: Why Does the Media Shun Hydroxychloroquine?

Algeria: 90% of cases have responded very well to this treatment protocol – HCQ proves effective